Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$7.14 - $8.53 $3,462 - $4,137
-485 Reduced 1.64%
29,047 $209,000
Q4 2022

Feb 14, 2023

SELL
$8.22 - $10.76 $5,975 - $7,822
-727 Reduced 2.4%
29,532 $243,000
Q3 2022

Nov 14, 2022

SELL
$8.95 - $12.0 $8,735 - $11,712
-976 Reduced 3.12%
30,259 $320,000
Q2 2022

Aug 15, 2022

SELL
$6.46 - $10.02 $10,633 - $16,492
-1,646 Reduced 5.01%
31,235 $289,000
Q1 2022

May 16, 2022

SELL
$5.56 - $7.99 $3,224 - $4,634
-580 Reduced 1.73%
32,881 $226,000
Q4 2021

Feb 14, 2022

SELL
$5.26 - $8.3 $725 - $1,145
-138 Reduced 0.41%
33,461 $269,000
Q3 2021

Nov 15, 2021

BUY
$2.7 - $6.64 $1,679 - $4,130
622 Added 1.89%
33,599 $206,000
Q2 2021

Aug 16, 2021

BUY
$3.11 - $4.61 $3,663 - $5,430
1,178 Added 3.7%
32,977 $103,000
Q1 2021

May 14, 2021

SELL
$3.03 - $4.58 $3,932 - $5,944
-1,298 Reduced 3.92%
31,799 $122,000
Q4 2020

Feb 16, 2021

SELL
$2.27 - $3.3 $5,211 - $7,576
-2,296 Reduced 6.49%
33,097 $101,000
Q3 2020

Nov 16, 2020

SELL
$2.14 - $12.02 $21,051 - $118,240
-9,837 Reduced 21.75%
35,393 $80,000
Q2 2020

Aug 14, 2020

BUY
$8.88 - $11.15 $14,545 - $18,263
1,638 Added 3.76%
45,230 $465,000
Q1 2020

May 15, 2020

SELL
$5.77 - $10.85 $40,436 - $76,036
-7,008 Reduced 13.85%
43,592 $435,000
Q4 2019

Feb 14, 2020

BUY
$5.76 - $7.6 $61,056 - $80,560
10,600 Added 26.5%
50,600 $385,000
Q3 2019

Nov 14, 2019

BUY
$6.24 - $8.84 $249,600 - $353,600
40,000 New
40,000 $256,000

Others Institutions Holding BLU

# of Institutions
1
Shares Held
128K
Call Options Held
0
Put Options Held
0

About BELLUS Health Inc.


  • Ticker BLU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 125,793,000
  • Description
  • BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...
More about BLU
Track This Portfolio

Track Weiss Multi Strategy Advisers LLC Portfolio

Follow Weiss Multi Strategy Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Weiss Multi Strategy Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Weiss Multi Strategy Advisers LLC with notifications on news.